New research has showed that the majority of patients achieving high rates of glucose control and weight loss in the first year of tirzepatide treatment have sustained success in the second year; however, factors predicting a sustained response are less clear for weight loss,.
The findings are from the SURPASS-4 trial in which patients with poorly controlled type 2 diabetes, obesity, and a risk for cardiovascular events were randomized to one of three doses of tirzepatide. Patients had a mean baseline A1c of 8.5% and a mean baseline body weight of 90.3 kg.
“The analysis shows that in the SURPASS-4 trial, approximately 80% of individuals who were treated with tirzepatide and who reached an A1c of 6.5% or weight loss > 10% at 52 weeks retained those [achievements] at 104 weeks,” said first author Steven Kahn, MD, of the VA Puget Sound Health Care System and University of Washington, Seattle.
To find out more, CLICK HERE.
